企業を読み込み中
Keep exploring
The themes Novartis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1.35TA+
JNJJohnson & Johnson$682.6BA+
MRKMerck & Co., Inc.$362.2BA
AMGNAmgen Inc.$252.6BA+
GILDGilead Sciences, Inc.$208.3BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
どうやって稼いでいるか
- Prescription medicines
競合
何を売っているか6
Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.
さらに3件を表示
Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.
誰が買っているか5
- Drug wholesalers buy medicines for resale to pharmacies and healthcare providers.
- Retail and specialty pharmacies dispense medicines to patients, including drugs that need special handling.
- Hospitals and private health systems buy medicines for treatment in their facilities.
さらに2件を表示
- Government agencies and government-supported health systems buy or fund medicines for patients.
- Insurers and managed-care organizations influence which medicines are covered and reimbursed.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1Sales of branded medicines depend on patent rights and regulatory exclusivity; generic or biosimilar competitors can enter after protections expire or are successfully challenged.
- 2Some medicines depend on licenses, collaborations or other agreements with outside drug developers.
- 3Manufacturing depends on specialized materials and tightly controlled production processes; some products may have limited alternative suppliers.
- 4Access to medicines depends on health-authority approval and on insurers or government health systems deciding whether and how much to reimburse.
うまくいかなくなる可能性
- 1Generic competition and patent challenges can reduce sales when drug protections expire or competitors successfully challenge them; Novartis has also faced generic erosion for established medicines.
- 2Government price controls, Medicare price negotiations, required rebates and insurer coverage decisions can limit the prices Novartis receives or restrict patient access.
- 3Drug candidates can fail clinical trials or fail to receive approval after years of research and testing, leaving Novartis without a marketable medicine and with development costs already incurred.
Novartis AGについて
Novartis researches, tests, manufactures and sells prescription medicines in about 120 countries (2025, high). Its research focuses on heart, kidney and metabolic diseases, immune disorders, brain and nerve diseases, and cancer. Net sales were USD 54.532 billion (FY2025, high).
- 本社
- Basel, Switzerland
- 設立
- 1996
- 従業員数
- 75,267 (December 31, 2025, high)
- 上場市場
- NYSE
- 決算期
- December 31
Novartis AG 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。